Nanobody inhibitors of Plexin-B1 identify allostery in plexin–semaphorin interactions and signaling
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.104740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Richard Cowan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cell Biology, Leicester Institute of Structural and Chemical Biology, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Semaphorins, Single-Domain Antibodies, Cell Adhesion Molecules. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LifeArc, European Synchrotron Radiation Facility.
Abstract (Originalsprache)
Plexin-B1 is a receptor for the cell surface semaphorin, Sema4D. This signaling system has been implicated in a variety of human diseases, including cancer, multiple sclerosis and osteoporosis. While inhibitors of the Plexin-B1:Sema4D interaction have been previously reported, understanding their mechanism has been hindered by an incomplete structural view of Plexin-B1. In this study, we have raised and characterized a pair of nanobodies that are specific for mouse Plexin-B1 and which inhibit the binding of Sema4D to mouse Plexin-B1 and its biological activity. Structural studies of these nanobodies reveal that they inhibit the binding of Sema4D in an allosteric manner, binding to epitopes not previously reported. In addition, we report the first unbound structure of human Plexin-B1, which reveals that Plexin-B1 undergoes a conformational change on Sema4D binding. These changes mirror those seen upon binding of allosteric peptide modulators, which suggests a new model for understanding Plexin-B1 signaling and provides a potential innovative route for therapeutic modulation of Plexin-B1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cell Biology, Leicester Institute of Structural and Chemical Biology, University of Leicester, Leicester, UK.
- LifeArc, Centre for Therapeutics Discovery, Stevenage, UK.
- Institute of Pharmacology, University of Marburg, Marburg, Germany; Department of Pharmacology, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
- Department of Pharmacology, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
- Department of Molecular and Cell Biology, Leicester Institute of Structural and Chemical Biology, University of Leicester, Leicester, UK. Electronic address: gh126@leicester.ac.uk.
Förderung
- LifeArc
- European Synchrotron Radiation Facility
Zitieren
APA
Cowan, R., Trokter, M., Oleksy, A., Fedorova, M., Sawmynaden, K., Worzfeld, T., Offermanns, S., Matthews, D., Carr, M. D., & Hall, G. (2023). Nanobody inhibitors of Plexin-B1 identify allostery in plexin–semaphorin interactions and signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.104740
Vancouver
Cowan R, Trokter M, Oleksy A, Fedorova M, Sawmynaden K, Worzfeld T, et al. Nanobody inhibitors of Plexin-B1 identify allostery in plexin–semaphorin interactions and signaling. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.104740
BibTeX
@article{Cowan2023,
author = {Cowan, Richard and Trokter, Martina and Oleksy, Arkadiusz and Fedorova, Marina and Sawmynaden, Kovilen and Worzfeld, Thomas and Offermanns, Stefan and Matthews, David and Carr, Mark D and Hall, Gareth},
title = {Nanobody inhibitors of Plexin-B1 identify allostery in plexin–semaphorin interactions and signaling},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.104740}
}
EUVIMED